Authors

Latest:

Dr. Manns on Risk Factors for Hepatitis C-Related Hepatocellular Carcinoma

Michael Manns, MD, the Director of the Department of Gastroenterology, Hepatology and Endocrinology at the Medical School of Hannover in Germany, explains risk factors for hepatitis C-related hepatocellular carcinoma.

Michael Marlan Mohundro, PharmD

Latest:

On the Horizon for Multiple Myeloma: Update on Novel Agents, Bone Therapies

A new generation of proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors are currently being investigated in clinical trials to treat patients with relapsed or refractory multiple myeloma.

Michael Marlon Mohundro, PharmD

Latest:

Clinical and Economic Considerations for the Use of Erythropoiesis-Stimulating Agents

Erythropoiesis-stimulating agents (ESAs) are genetically engineered forms of erythropoietin that stimulate erythropoiesis through direct or indirect action on the erythropoietin receptor producing an increase

Michael Mauro, MD

Latest:

Dr. Mauro on the Risks of Disease Progression in Myelofibrosis

Michael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.

Michael Mauro, MD, Memorial Sloan Kettering Cancer Center

Michael Morse, MD, Duke Cancer Institute

Michael P. Link, MD

Latest:

ASCO President Recaps Top Stories From Meeting

Dr. Michael P. Link, ASCO President, from Stanford University School of Medicine, on the top stories from the 2012 ASCO Annual Meeting.

Michael Palese, MD

Latest:

Dr. Palese on Emerging Technologies in Benign Prostatic Hyperplasia

Michael A. Palese, MD, discusses emerging technologies in benign prostatic hyperplasia.

Michael Pishvaian, MD, PhD

Latest:

Dr. Pishvaian Discusses Atezolizumab Plus Bevacizumab in HCC

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with hepatocellular carcinoma.

Michael Postow, MD

Latest:

Key Data on Combination Immunotherapies in BRAF-Mutated Melanoma with Brain Metastases

Doctors discuss the effectiveness of different treatment combinations for patients with BRAF-mutated metastatic melanoma and brain metastases, highlighting that consideration of patient preferences is essential in making treatment decisions.

Michael Postow, MD, Memorial Sloan Kettering Cancer Center

Michael Pulsipher, MD

Latest:

Pivotal Data in NHL and Pediatric Cancers at ASH 2021: Insight From Drs. Loretta Nastoupil and Michael Pulsipher

OncLive speaks with Dr. Loretta Nastoupil on some exciting non-Hodgkin lymphoma studies and Dr. Michael Pulsipher on some intriguing pediatric cancer research.

Michael Pulsipher, MD, Children

Michael R. Bishop, MD, University of Chicago

Latest:

Dr Bishop on 34-Month Data With Anitocabtagene Autoleucel in R/R Myeloma

Michael R. Bishop, MD, discusses 34-month data from the iMMagine-1 trial of anitocabtagene autoleucel in relapsed/refractory myeloma.

Michael R. Charlton, MD, MBBS

Latest:

Dr. Charlton on the Interaction Between Liver Disease and HCC

Michael R. Charlton, MD, MBBS, discusses the interaction between liver disease and hepatocellular carcinoma.

Michael R. Harrison, MD

Latest:

Dr. Harrison on the Investigation of Combination Strategies in Frontline RCC

Michael R. Harrison, MD, discusses several ongoing or upcoming studies that may change the treatment paradigm in renal cell carcinoma.

Michael R. Harrison, MD, Duke Cancer Institute

Michael R. Page, PharmD, RPh

Latest:

Chemotherapy Parity Laws Ignore Cost, Quality Question

With the FDA approval of several oral chemotherapy agents, the cost of medications to treat cancer is increasing rapidly. To control costs, legislators, patient advocates, and physicians have pushed for oral chemotherapy parity laws.

Michael Reff, RPh, MBA National Community Oncology Dispensing Association

Michael Rosenzweig, MD

Latest:

Dr. Rosenzweig Discusses the Standard of Care in Amyloidosis

Michael Rosenzweig, MD, assistant professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses the standard of care for the treatment of patients with amyloidosis.